Chimeric Therapeutics Ltd
ASX:CHM

Watchlist Manager
Chimeric Therapeutics Ltd Logo
Chimeric Therapeutics Ltd
ASX:CHM
Watchlist
Price: 0.003 AUD -25% Market Closed
Market Cap: 10.9m AUD

Gross Margin
Chimeric Therapeutics Ltd

78.7%
Current
11%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.7%
=
Gross Profit
3.1m
/
Revenue
4m

Gross Margin Across Competitors

No Stocks Found

Chimeric Therapeutics Ltd
Glance View

Market Cap
10.9m AUD
Industry
Biotechnology

Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.

CHM Intrinsic Value
0.007 AUD
Undervaluation 57%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
78.7%
=
Gross Profit
3.1m
/
Revenue
4m
What is the Gross Margin of Chimeric Therapeutics Ltd?

Based on Chimeric Therapeutics Ltd's most recent financial statements, the company has Gross Margin of 78.7%.

Back to Top